We are live on ! Find out more
LPCN icon

Lipocine
LPCN

46 hedge funds and large institutions have $4.85M invested in Lipocine in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,000% more call options, than puts

Call options by funds: $496K | Put options by funds: $16K

0% more funds holding

Funds holding: 46 → 46 (0)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

0.07% less ownership

Funds ownership: 0.79% → 0.72% (-0.07%)

49% less capital invested

Capital invested by funds: $9.54M → $4.85M (-$4.69M)

60% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 10

Holders
46
Holders Change
–
Holders Change %
0%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
10
Closed
7
Calls
$496K
Puts
$16K
Net Calls
+$480K
Net Calls Change
-$412K

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$194K
2
Renaissance Technologies
Renaissance Technologies
New York
+$77.8K
3
VF
Virtu Financial
New York
+$61.4K
4
EWA
EP Wealth Advisors
California
+$17.5K
5
KPWS
Kestra Private Wealth Services
Texas
+$9.5K

Top Sellers

1
Marshall Wace
Marshall Wace
United Kingdom
-$353K
2
WE
Wealth Effects
Massachusetts
-$174K
3
BlackRock
BlackRock
New York
-$104K
4
Mercer Global Advisors
Mercer Global Advisors
Colorado
-$98.5K
5
Two Sigma Investments
Two Sigma Investments
New York
-$87.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.71M – – –
BlackRock
2
BlackRock
New York
$655K -$104K -9,296 -10%
WE
3
Wealth Effects
Massachusetts
$547K -$174K -15,558 -18%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$374K – – –
BCM
5
Bridgeway Capital Management
Texas
$192K – – –
Two Sigma Investments
6
Two Sigma Investments
New York
$146K -$87.7K -7,854 -29%
State Street
7
State Street
Massachusetts
$142K – – –
Citadel Advisors
8
Citadel Advisors
Florida
$133K +$194K +17,377 New
KAS
9
Kestra Advisory Services
Texas
$124K +$983 +88 +0.5%
Two Sigma Advisers
10
Two Sigma Advisers
New York
$94K -$65.7K -5,883 -32%
Renaissance Technologies
11
Renaissance Technologies
New York
$90K +$77.8K +6,964 +146%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$84K – – –
Mercer Global Advisors
13
Mercer Global Advisors
Colorado
$72K -$98.5K -8,824 -49%
Northern Trust
14
Northern Trust
Illinois
$72K – – –
VF
15
Virtu Financial
New York
$42K +$61.4K +5,495 New
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$37K – – –
MML Investors Services
17
MML Investors Services
Massachusetts
$35K – – –
Millennium Management
18
Millennium Management
New York
$33K -$83.4K -7,470 -63%
CL
19
Choreo LLC
Illinois
$29K – – –
LPL Financial
20
LPL Financial
California
$28K – – –
Bank of New York Mellon
21
Bank of New York Mellon
New York
$24K – – –
Charles Schwab
22
Charles Schwab
California
$23K – – –
AWA
23
Aaron Wealth Advisors
Illinois
$20K -$65.7K -5,882 -69%
Ameriprise
24
Ameriprise
Minnesota
$20K -$14.8K -1,324 -34%
Morgan Stanley
25
Morgan Stanley
New York
$16K -$14.1K -1,262 -38%
1
2

LPCN Hedge Fund Activity: Q3 2022 in Review

46 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2022, worth a combined $4.85M — down 49% from $9.54M a quarter earlier.

Fund positioning in LPCN was balanced in Q3 2022: 7 funds opened new positions, 7 closed out, 4 added to existing stakes and 10 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $194K. The largest seller was Marshall Wace, exiting entirely with an estimated $353K sold.

  • 46 institutional investors held Lipocine (LPCN) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $4.85M of Lipocine stock for Q3 2022, down 49% quarter-over-quarter.
  • 7 funds opened new Lipocine positions in Q3 2022 and 7 closed out, a net change of 0 holders.
  • The largest Lipocine buyer in Q3 2022 was Citadel Advisors, an estimated $194K added.
  • The largest Lipocine seller in Q3 2022 was Marshall Wace, an estimated $353K sold.

Based on aggregated 13F filings for Q3 2022.